TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03317860

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train
Study: NCT03604367

Intervention type: DEVICE
Intervention: GAITRite assessment
Description: The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
Study: NCT00115570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Subcutaneous injection once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin
Description: subcutaneous injection twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: subcutaneous injection twice daily
Study: NCT00287105

Intervention type: DRUG
Group type: OTHER
Intervention: Standard chemotherapy + Imatinib
Description: Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase

Intervention type: DRUG
Group type: OTHER
Intervention: Standard chemotherapy + Imatinib
Description: Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
Study: NCT02720393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-carrageenan diet
Description: Diet of food items that have no carrageenan as selected by study dietician.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: Diet of food items that have carrageenan as selected by study dietician
Study: NCT00442169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 Low Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 Medium Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 High Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline solution
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 High Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl solution
Description: Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Study: NCT01921205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects \<30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)
Study: NCT04356222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion once every two weeks ,once 10mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Intrathecal chemotherapy specified dose on specified days
Study: NCT01149850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study: NCT03596216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENS
Description: This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
Study: NCT02456012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral esomeprazole 20 mg twice daily
Description: for 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral esomeprazole 20 mg once daily
Description: for 36 weeks
Study: NCT03908034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: presence of uncontrollable risk factor
Description: the presence of an uncontrollable / unremovable risk factor for a disease

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: presence of uncontrollable risk factor
Description: the presence of an uncontrollable / unremovable risk factor for a disease

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of anticipated regret
Description: higher level of elaboration on potential regret

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of anticipated regret
Description: higher level of elaboration on potential regret
Study: NCT00758732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
Study: NCT00987376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy
Description: C11 Choline, C11 Acetate PET and MRI
Study: NCT01457651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment
Description: Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment
Description: Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment
Description: Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment
Description: Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)
Study: NCT05475249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant placement and prothesis made with different types of abutment
Description: Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Implant placement and prothesis made with different types of abutment
Description: Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
Study: NCT01089504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenobarbital
Description: Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo, same volume as active drug, by mouth daily for 4 months
Study: NCT02740946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
Study: NCT01924845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
Study: NCT04265963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123 CAR-T cells
Description: CD123 CAR-T cell therapy
Study: NCT02739230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: On-Q pain intra-articular catheter
Study: NCT02485782

Intervention type: DEVICE
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)

Intervention type: DEVICE
Intervention: BCM- Body Composition Monitor, Fresenius Medical Care
Description: Information about the individual fluid status and the nutritional status.
Study: NCT03969485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Hybrid Fractional Laser Device
Study: NCT02485782

Intervention type: DEVICE
Intervention: SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 15 min during hemodialysis
Study: NCT04661956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)
Description: Transbronchial lung biopsy by cryoprobe or by forcep

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)
Description: Transbronchial lung biopsy by cryoprobe or by forcep
Study: NCT01825928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo group,3mg/pill,3mg/day forced titration method,last 84 days
Study: NCT03596034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5%, Virginia Tobacco, ENDS product
Description: Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
Study: NCT04268459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provox prosthesis exchange
Description: Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provox prosthesis exchange
Description: Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
Study: NCT02868112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Oncology Care
Description: Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdisciplinary Intervention
Description: Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
Study: NCT02190526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine(asacol 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo like asacol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo like asacol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo like amitriptyline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo like amitriptyline
Study: NCT01633918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-supported FeetEnergy approach
Description: Three health education lessons and two homework's about increasing physical activity and reducing screen time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual health education
Description: Usual health education lessons
Study: NCT01445444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training
Description: * 8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~* The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~* components:~* Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~* Session 2. implement habit reversal, including awareness training, competing response training, and social support.~* Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Reversal Training
Description: * 8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~* The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~* components:~* Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~* Session 2. implement habit reversal, including awareness training, competing response training, and social support.~* Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy.
Study: NCT04481412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical cetirizine
Description: Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 96% ethanol that will be applied once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil
Description: Topical Minoxidil 5% that will be applied once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical minoxidil
Description: Topical Minoxidil 5% that will be applied once daily.
Study: NCT01349426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LigaSure Force Triad Vessel Sealing System
Description: Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure Force Triad Vessel Sealing System
Description: Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
Study: NCT03397979

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infrequent versus Frequent Soaking Baths
Description: Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infrequent versus Frequent Soaking Baths
Description: Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
Study: NCT02832648

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: selenase (selenium)
Description: Selenase (Biosyn, Germany) Sodium selenite pentahydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenase (selenium)
Description: Selenase (Biosyn, Germany) Sodium selenite pentahydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenase (selenium)
Description: Selenase (Biosyn, Germany) Sodium selenite pentahydrate
Study: NCT03164668

Intervention type: OTHER
Group type: OTHER
Intervention: menthol flavored e-cigarette
Description: menthol flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: menthol flavored e-cigarette
Description: menthol flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: menthol flavored e-cigarette
Description: menthol flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: menthol flavored e-cigarette
Description: menthol flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: tobacco flavored e-cigarette
Description: tobacco flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: tobacco flavored e-cigarette
Description: tobacco flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: tobacco flavored e-cigarette
Description: tobacco flavored e-cigarette

Intervention type: OTHER
Group type: OTHER
Intervention: tobacco flavored e-cigarette
Description: tobacco flavored e-cigarette
Study: NCT02251262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body 18FDG-PET-CT scan
Description: 18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
Study: NCT03732573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Text messages conveying 3 specific behaviour change techniques
Study: NCT01032616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threonine Experimental: Study Period 1
Description: Enteral and parenteral infusion of threonine isotope

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lysine Experimental: Study Period 2
Description: Both intravenous (iv) and intragastric (ig) Lysine isotopes.